Skip to content

Effect of laser therapy treatment on diabetic peripheral neuropathic pain in older adults

A pilot randomized clinical trial on the effect of Laser Therapy treatment on diabetic peripheral neuropathic pain in older adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/06/008739
Enrollment
40
Registered
2017-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- persons with type 2 diabetes mellitus

Interventions

Intervention1: Deep tissue Laser therapy: For the 3-month intervention period, participants enrolled in the study will receive: (a) laser treatment twice-per-week for 4 weeks and once-per-week for 8

Sponsors

Lab India Pvt limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes 2. Chronic, unresolved neuropathic pain of the feet for more than 3 months 3. Age 60 or older 4. English/Hindi speaking 5. From Delhi and National capital region, so that able to meet the treatment schedule and easily be followed up. 6. Previous integrative medicine, dietary supplementation, or other alternative approaches for diabetic neuropathic pain are permitted, but diary of use must be kept during trial.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Lower extremity open wounds 3. Psychiatric diagnosis of schizophrenia, other psychotic disorders, bipolar disorder, major depression with psychotic features, delirium, and alcohol or substance abuse/dependence 4. Bleeding disorders 5. Aphasia or sensory, motor, and/or visual disturbances that could interfere with assessments 6. Patient with life expectancy less than 3 years, due to end stage diseases of any vital organ like renal, thyroid, hepatic, gastrointestinal, or seizure. 7. Any malignancy treatedwith chemotherapy or radiotherapy in the previous two years 8. T-score > 70 on the Global Severity Index of the Brief Symptoms Inventory (BSI; Derogatis&Melisaratos, 1983) 9. A score 29 or higher on the Beck Depression Inventory-II (BDI; Beck, Steer, & Brown, 1996) 10. Severe cognitive impairment by score of 17 or less in MMSE scale

Design outcomes

Primary

MeasureTime frame
Effect of laser therapy will be measured on following : 1.Pain 2.IMMUNE Function 3.Health, Functional Status, and life satisfaction measures 4. Quantitative assessmentTimepoint: patient will be evaluated before and after intervention ( 0 and 3 months)

Secondary

MeasureTime frame
Effect of laser therapy will be measured on following : 1.Pain 2.IMMUNE Function 3.Health, Functional StaTimepoint: after 12 weeks of therapy

Countries

India

Contacts

Public ContactDr Prashun Chatterjee

AIIMS, New Delhi

drprasun.geriatrics@gmail.com9868397294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 20, 2026